Private Trust Co. NA grew its stake in shares of KKR & Co. Inc. (NYSE:KKR – Free Report) by 189.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,604 shares of the asset manager’s stock after buying an additional 1,705 shares during the period. Private Trust Co. NA’s holdings in KKR & Co. Inc. were worth $340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of the stock. Versant Capital Management Inc increased its holdings in KKR & Co. Inc. by 622.9% in the 2nd quarter. Versant Capital Management Inc now owns 253 shares of the asset manager’s stock valued at $27,000 after acquiring an additional 218 shares during the last quarter. Mather Group LLC. grew its position in shares of KKR & Co. Inc. by 371.4% during the second quarter. Mather Group LLC. now owns 264 shares of the asset manager’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in shares of KKR & Co. Inc. in the third quarter worth about $31,000. Raleigh Capital Management Inc. lifted its position in shares of KKR & Co. Inc. by 56.7% in the third quarter. Raleigh Capital Management Inc. now owns 235 shares of the asset manager’s stock worth $31,000 after buying an additional 85 shares in the last quarter. Finally, Eastern Bank bought a new position in KKR & Co. Inc. during the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on KKR. Redburn Atlantic started coverage on KKR & Co. Inc. in a research note on Tuesday, August 27th. They issued a “buy” rating and a $153.00 price objective on the stock. HSBC started coverage on shares of KKR & Co. Inc. in a research note on Wednesday, September 18th. They set a “buy” rating and a $148.00 price target on the stock. Argus raised shares of KKR & Co. Inc. to a “strong-buy” rating in a research note on Thursday, August 1st. Evercore ISI increased their price target on shares of KKR & Co. Inc. from $135.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Barclays lifted their price target on KKR & Co. Inc. from $149.00 to $166.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $154.14.
Insider Buying and Selling
In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the sale, the insider now directly owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. This represents a 18.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Kkr Group Partnership L.P. bought 11,619,998 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were acquired at an average cost of $11.13 per share, for a total transaction of $129,330,577.74. Following the transaction, the insider now directly owns 92,959,984 shares in the company, valued at approximately $1,034,644,621.92. This trade represents a 14.29 % increase in their position. The disclosure for this purchase can be found here. 39.34% of the stock is owned by insiders.
KKR & Co. Inc. Stock Down 0.7 %
NYSE:KKR opened at $160.13 on Thursday. The company has a market cap of $142.23 billion, a price-to-earnings ratio of 48.67, a price-to-earnings-growth ratio of 1.26 and a beta of 1.61. KKR & Co. Inc. has a twelve month low of $68.89 and a twelve month high of $162.73. The company has a current ratio of 0.07, a quick ratio of 0.07 and a debt-to-equity ratio of 0.82. The stock has a fifty day simple moving average of $141.61 and a 200-day simple moving average of $122.59.
KKR & Co. Inc. (NYSE:KKR – Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The asset manager reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.35. The company had revenue of $4.79 billion during the quarter, compared to analyst estimates of $1.23 billion. KKR & Co. Inc. had a net margin of 13.21% and a return on equity of 5.77%. During the same quarter last year, the business posted $0.73 EPS. Analysts anticipate that KKR & Co. Inc. will post 4.16 EPS for the current year.
KKR & Co. Inc. Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, November 19th. Investors of record on Monday, November 4th were issued a $0.175 dividend. The ex-dividend date was Monday, November 4th. This represents a $0.70 dividend on an annualized basis and a dividend yield of 0.44%. KKR & Co. Inc.’s payout ratio is 21.28%.
About KKR & Co. Inc.
KKR & Co Inc is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market and middle market investments.
Featured Stories
- Five stocks we like better than KKR & Co. Inc.
- Industrial Products Stocks Investing
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Quiet Period Expirations Explained
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for KKR & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KKR & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.